




CALQUENCE—A BTKi for the Treatment of CLL/SLL: With Updated Clinical Trial Data and Tablet Formulation



PRESENTED BY:

Elizabeth Brem, MD

UC Irvine Health
Orange, CA



Thursday, February 23, 2023



9:00 AM – 9:45 AM
Hawaii Standard Time



Hilton Hawaiian Village/Honolulu 1
Honolulu, HI 96815

This is a non-CE session held
in-conjunction with PRIMO 2023



CALQUENCE[®]
acalabrutinib 100 mg tablets

INDICATION AND USAGE

CALQUENCE is a Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

SELECT SAFETY INFORMATION

Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, and atrial fibrillation and flutter. The most common adverse reactions ($\geq 30\%$) of any grade in patients with CLL were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.

Please see accompanying full Prescribing Information, including Patient Information.

This program is intended for US healthcare professionals only.

AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense associated with this event. AstraZeneca fully supports and abides by the PhRMA Code on Interactions With Healthcare Professionals (HCPs). This program is open only to HCP invitees. AstraZeneca will not accommodate attendance of a spouse or other guest of any HCP attendee, nor will AstraZeneca pay for transportation or parking costs of attendees. If you are a prescriber and/or a Federal, State, or institution employee, you may be subject to laws, regulations, or rules that prohibit or limit your receipt of gifts, meals, or items of value. We ask that you comply with any such restrictions. This is a presentation sponsored directly by AstraZeneca and there are no continuing medical education (CME), continuing nursing education (CNE), or continuing education (CE) credits associated with this activity. AstraZeneca will not recommend, endorse, or support the submission of this promotional program for CE credits.

